Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 43

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 3
Chunk 43
---
 establishment or amendment of certain equity-based compensation plans, an issuance that will result in a change of control
of the company, certain transactions other than a public offering involving issuances of a 20% or more interest in the company and certain
acquisitions of the stock or assets of another company. Following our home country governance practices as opposed to the requirements
that would otherwise apply to a U. S. company listed on Nasdaq may provide less protection than is accorded to investors under the Nasdaq
Rules applicable to U. S. domestic issuers. See “ Item 16G - Corporate Governance - Nasdaq Listing Rules and Home Country
Practices.”

In addition, as a foreign private issuer, we are exempt from the
rules and regulations under the U. S. Securities Exchange Act of 1934, as amended, or the Exchange Act, related to the furnishing and content
of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery
provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file annual, quarterly
and current reports and financial statements with the SEC as frequently or as promptly as domestic companies whose securities are registered
under the Exchange Act.

If we fail to comply with the continued listing
requirements of the Nasdaq Capital Market, our ADSs may be delisted and the price of our ADSs and our ability to access the capital markets
could be negatively impacted.

Our ADSs are listed on the Nasdaq Capital Market. As such, we are
required to meet the continued listing requirements of the Nasdaq Capital Market and other Nasdaq rules, including those regarding director
independence and independent committee requirements, minimum shareholders’ equity, minimum share price and certain other corporate
governance requirements. In particular, we are required to maintain a minimum bid price for our listed ADSs of $1.00 per share.

On May 13, 2024, we were notified by the Nasdaq Stock Market, LLC,
or Nasdaq, that we were not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued
listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00
per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the